Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Pharmacogenomic Contributions to Trihexyphenidyl Biotransformation and Response in Children With Dystonic Cerebral Palsy	Brain Damage, Chronic, Cerebral Palsy, Athetoid, Cerebral Palsy, Dystonic-Rigid, Disease Attributes, Dyskinesias, Dystonia, Secondary, Neurologic Manifestations, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, brain disorder, central nervous system disorder, cerebral palsy, disease susceptibility, dystonic disorder, inherited disease susceptibility, movement disorder, nervous system disorder	Recruiting	Phase 1	2026-06-24		NCT06554288

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Children's Mercy Hospital Kansas City	36
University of Kansas Medical Center	169

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Children's Mercy Hospital Kansas City	Kansas City	United States	3